首页> 外文期刊>American journal of medical quality: the official journal of the American College of Medical Quality >Enhanced Assessment of Chest Pain and Related Symptoms in the Primary Care Setting Through the Use of a Novel Personalized Medicine Genomic Test: Results From a Prospective Registry Study
【24h】

Enhanced Assessment of Chest Pain and Related Symptoms in the Primary Care Setting Through the Use of a Novel Personalized Medicine Genomic Test: Results From a Prospective Registry Study

机译:通过使用新的个性化医学基因组测试,增强胸痛和相关症状的评估和相关症状:潜在注册表研究的结果

获取原文
获取原文并翻译 | 示例
           

摘要

Novel approaches for assessing patients with chest pain and related symptoms may improve outpatient care. The REGISTRY I study measured the impact of a personalized gene expression score (GES) on subsequent cardiac referral decisions by primary care providers. Of the 342 stable, nonacute patients evaluated, the mean age was 55 years, 53% were female, and mean (SD) GES was 16 (+/- 10) (range = 1-40). Low GES (15), indicating a low current likelihood of obstructive coronary artery disease (CAD), was observed in 49% of patients. After clinical covariate adjustment, each 10-point GES decrease was associated with a 14-fold decreased odds of cardiac referral (P < .0001). Low GES patients had 94% reduced odds of referral relative to elevated GES patients (P < .0001), with follow-up supporting a favorable safety profile. This genomic-based test demonstrated clinical utility by guiding decision making during assessment of symptomatic patients with suspected obstructive CAD.
机译:评估胸痛和相关症状患者的新方法可能会改善门诊病。 注册表我研究通过初级保健提供者测量了个性化基因表达评分(GES)对随后的心脏转诊决策的影响。 在342稳定,非敏捷患者中评估,平均年龄为55岁,雌性53%,平均值(SD)GES为16(+/- 10)(范围= 1-40)。 在49%的患者中观察到低GES(15),表明阻塞性冠状动脉疾病(CAD)的低电流可能性。 在临床调整后,每10点GES降低与心脏引发的14倍降低有14倍(P <.0001)。 低GES患者相对于升高的GES患者(P <0.0001),引用的几率降低了94%,随访支持有利的安全性。 基于基因组的测试通过在评估症状性障碍CAD的症状患者期间引导决策来表现出临床效用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号